ECM Transactions

• TenNor Therapeutics (Suzhou) Limited (6872.HK) in its approximately US$80 million IPO and listing on the Hong Kong Stock Exchange
• Cofoe Medical Technology Co., Ltd. in its approximately US$136 million listing of H shares on the Hong Kong Stock Exchange, first dual A+H listing for home care medical devices company
• Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK) in its approximately US$101 million IPO and listing on the Hong Kong Stock Exchange, first IPO of a medical imaging AI model
• Shenzhen Woer Heat-Shrinkable Material Co., Ltd. (9981.HK) in its approximately US$363 million IPO and listing on the Hong Kong Stock Exchange
• CICC Hong Kong Securities and Citigroup Global Markets as joint sponsors and other underwriters in the approximately US$235 million IPO of Suzhou Ribo Life Science Co., Ltd. (6938.HK) on the Hong Kong Stock Exchange, the second largest Chapter 18A Hong Kong IPO since 2022
• Vigonvita Life Sciences Co., Ltd. (2630.HK) in its approximately HK$600 million (approximately US$77 million) IPO and listing on the Hong Kong Stock Exchange
• Shuangdeng Group Co., Ltd. (6960.HK) in its approximately US$110 million IPO and listing on the Hong Kong Exchange
• TransThera Sciences (2617.HK) in approximately US$25 million listing of H shares on the Hong Kong Exchange
• CICC and Huatai International as joint sponsors, and other underwriters, in approximately US$25 million IPO of Shouhui Group Limited (2621.HK) on the Hong Kong Stock Exchange
• Hainan Drinda New Energy Technology (2865.HK) in its approximately US$180 million listing of H shares on the Hong Kong Stock Exchange, first dual A+H listing for China-based PV Cell Company
• CICC as sole sponsor and 20 other underwriters in approximately US$85 million IPO of Shanghai Voicecomm Information Technology Co., Ltd. (2495.HK) on the Hong Kong Stock Exchange
• CICC as the sole sponsor and overall coordinator in the approximately US$31 million IPO of Qyuns Therapeutics Co., Ltd. (2509.HK) on the Hong Kong Stock Exchange
• Folangsi Co., Ltd (2499.HK) in its HK$155 million (approximately US$20.15 million) IPO and listing on the Hong Kong Stock Exchange
• Beijing UBOX Online Technology Corp. (2429.HK) in its approximately US$30 million IPO and listing on the Hong Kong Stock Exchange, marking the first Hong Kong listing of a company in the unmanned retail industry
• 3D Medicines Inc. in its US$52 million IPO and listing on the Hong Kong Stock Exchange
• Rainmed Medical Limited in its IPO and listing on the Hong Kong Stock Exchange
• Kangqiao Service Group Limited in its US$82.9 million IPO and listing on the Hong Kong Stock Exchange
• CCB International Capital Limited as the sole sponsor and other underwriters in the US$98.5 million IPO and listing of Dexin Services Group Limited on the Hong Kong Stock Exchange
• ABCI Capital Limited, CLSA Capital Markets Limited and Haitong International Capital Limited as the joint sponsors and other underwriters in the US$331 million IPO and listing of Radiance Holdings (Group) Company Limited on the Hong Kong Stock Exchange
• Credit Suisse (Hong Kong) Limited, Morgan Stanley Asia Limited and ICBC International Capital Limited as the joint sponsors and other underwriters in the US$381 million IPO and listing of JS Global Lifestyle Company Limited on the Hong Kong Stock Exchange
• CCB International Capital Limited as the sole sponsor and other underwriters in the US$189 million IPO and listing of Dexin China Holdings Company Limited on the Hong Kong Stock Exchange

* Including work performed prior to joining O’Melveny